Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Fiala

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
Patient Preference and Adherence|March 8, 2022
Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United StatesDaniel Auclair, Carol Mansfield, Mark A Fiala, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 10, 2015
Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic SyndromeIskra Pusic, Jaebok Choi, Mark A Fiala, et al.
Leukemia & Lymphoma|May 14, 2013
The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomideTzu-Fei Wang, Rohan Ahluwalia, Mark A Fiala, et al.
Gynecologic Oncology|March 2, 2021
A deficit-accumulation frailty index predicts survival outcomes in patients with gynecologic malignancyMary M Mullen, Tyler R McKinnish, Mark A Fiala, et al.
Leukemia Research|August 10, 2016
Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantationArmin Ghobadi, Jaebok Choi, Mark A Fiala, et al.
Blood Advances|October 7, 2025
Ablation of CD38 in Multiple Myeloma Cells Leads to an Aggressive Phenotype in a Mouse Xenograft ModelMichael Riley Dyer, Alexander Zheleznyak, Erin N Teubner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2020
VLA4-Targeted Nanoparticles Hijack Cell Adhesion-Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong SurvivalFrancesca Fontana, Michael J Scott, John S Allen, et al.
Transplantation and Cellular Therapy|August 19, 2023
Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell TransplantationZiheng Xu, Jaebok Choi, Matthew Cooper, et al.
Biorxiv : the Preprint Server for Biology|August 16, 2024
Somatic mutation phasing and haplotype extension using linked-reads in multiple myelomaSteven M Foltz, Yize Li, Lijun Yao, et al.
Leukemia|March 13, 2019
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapyUjjawal H Gandhi, Robert F Cornell, Arjun Lakshman, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Patient Preference and Adherence|March 8, 2022
Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United StatesDaniel Auclair, Carol Mansfield, Mark A Fiala, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 10, 2015
Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic SyndromeIskra Pusic, Jaebok Choi, Mark A Fiala, et al.
Leukemia & Lymphoma|May 14, 2013
The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomideTzu-Fei Wang, Rohan Ahluwalia, Mark A Fiala, et al.
Gynecologic Oncology|March 2, 2021
A deficit-accumulation frailty index predicts survival outcomes in patients with gynecologic malignancyMary M Mullen, Tyler R McKinnish, Mark A Fiala, et al.
Leukemia Research|August 10, 2016
Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantationArmin Ghobadi, Jaebok Choi, Mark A Fiala, et al.
Blood Advances|October 7, 2025
Ablation of CD38 in Multiple Myeloma Cells Leads to an Aggressive Phenotype in a Mouse Xenograft ModelMichael Riley Dyer, Alexander Zheleznyak, Erin N Teubner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2020
VLA4-Targeted Nanoparticles Hijack Cell Adhesion-Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong SurvivalFrancesca Fontana, Michael J Scott, John S Allen, et al.
Transplantation and Cellular Therapy|August 19, 2023
Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell TransplantationZiheng Xu, Jaebok Choi, Matthew Cooper, et al.
Biorxiv : the Preprint Server for Biology|August 16, 2024
Somatic mutation phasing and haplotype extension using linked-reads in multiple myelomaSteven M Foltz, Yize Li, Lijun Yao, et al.
Leukemia|March 13, 2019
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapyUjjawal H Gandhi, Robert F Cornell, Arjun Lakshman, et al.
Pageof 8